Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia.

Furman RR, Wierda WG, Patten PEM, Chaves JM, Brown JR, Munir T, Martin P, Awan FT, Stephens DM, Ghia P, Barrientos JC, Patel K, Woyach JA, de Borja M, Wang MH, Jain N, O'Brien SM, Byrd JC.

Open source

DOI: 10.1182/bloodadvances.2025018310
Published: 2026-06-01
Container: Blood Adv
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2025018310,
  title = {Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia.},
  author = {Furman RR and  Wierda WG and  Patten PEM and  Chaves JM and  Brown JR and  Munir T and  Martin P and  Awan FT and  Stephens DM and  Ghia P and  Barrientos JC and  Patel K and  Woyach JA and  de Borja M and  Wang MH and  Jain N and  O'Brien SM and  Byrd JC.},
  year = {2026},
  journal = {Blood Adv},
  doi = {10.1182/bloodadvances.2025018310},
  url = {https://doi.org/10.1182/bloodadvances.2025018310}
}

RIS

TY  - JOUR
TI  - Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia.
AU  - Furman RR
AU  -  Wierda WG
AU  -  Patten PEM
AU  -  Chaves JM
AU  -  Brown JR
AU  -  Munir T
AU  -  Martin P
AU  -  Awan FT
AU  -  Stephens DM
AU  -  Ghia P
AU  -  Barrientos JC
AU  -  Patel K
AU  -  Woyach JA
AU  -  de Borja M
AU  -  Wang MH
AU  -  Jain N
AU  -  O'Brien SM
AU  -  Byrd JC.
PY  - 2026
JO  - Blood Adv
DO  - 10.1182/bloodadvances.2025018310
UR  - https://doi.org/10.1182/bloodadvances.2025018310
ER  -

APA

RR, F., WG, W., PEM, P., JM, C., JR, B., T, M., P, M., FT, A., DM, S., P, G., JC, B., K, P., JA, W., M, D. B., MH, W., N, J., SM, O., & JC., B. (2026). Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia.. Blood Adv. https://doi.org/10.1182/bloodadvances.2025018310

Source records

europe-pmc · retrieved 2026-09-25T22:11:11.913Z